# DESCRIPTION

- claim priority to provisional patent application

## TECHNICAL FIELD

- define technical fields

## BACKGROUND OF THE INVENTION

- introduce Stat3 and its role in cancer
- discuss existing drugs and limitations

## SUMMARY OF THE INVENTION

- introduce virtual ligand screening approach
- describe pY-peptide binding pocket of Stat3 SH2 domain
- identify lead compounds and their properties
- discuss selectivity for Stat3 vs. Stat1
- describe methods for inhibiting Stat3 activity
- outline uses of the invention
- describe criteria for Stat3 inhibitors
- provide specific embodiments of the invention
- describe general formula for inhibitors
- discuss treatment of various cancers and diseases
- outline methods for identifying inhibitors of other STAT proteins

## DETAILED DESCRIPTION OF THE INVENTION

- incorporate by reference other patent applications
- describe Stat3 inhibitors by structure and method of development
- describe specific embodiments of the invention

### I. DEFINITIONS

- define "a" or "an" and "another"
- define "inhibitor"
- define "therapeutically effective amount"
- define "pharmaceutically acceptable"
- define "at risk for having cancer"
- define "binding affinity" and "domain"

### II. DERIVATIVES

- define "derivative"
- define "functionally active derivative"
- describe derivatives of specific compounds
- describe general formula for inhibitors
- describe another general formula for inhibitors
- describe yet another general formula for inhibitors
- describe obtaining derivatives by synthesis or commercial means

### III. EMBODIMENTS FOR TARGETING STAT3

- introduce STAT proteins
- describe Stat1 and Stat3 isoforms
- discuss Stat3α and Stat3β differences
- motivate targeting Stat3α while sparing Stat1
- describe targeting Stat3α while sparing Stat3β
- outline development of small-molecule Stat3 inhibitors
- discuss potential anti-tumor effects of Stat3 inhibitors

### IV. TARGETING CANCER STEM CELLS

- introduce importance of targeting cancer stem cells
- discuss role of Stat3 in cancer stem cells
- describe development of probes targeting Stat3
- outline screening process for Stat3 inhibitors
- discuss potential applications of Stat3 inhibitors in cancer therapy

### V. COMBINATION THERAPY

- introduce concept of combination therapy
- describe use of Stat3 inhibitor with another agent
- outline various combination therapy approaches
- discuss chemotherapy options
- describe radiotherapy options
- outline radiochemotherapy options
- discuss immunotherapy options
- describe gene therapy options
- outline surgical options

### VI. PHARMACEUTICAL COMPOSITIONS

- define pharmaceutical compositions
- describe pharmaceutically acceptable carriers
- outline administration routes and methods
- determine dosage amounts and concentrations
- describe composition formulations and ingredients
- discuss antioxidants and preservatives
- outline salt forms and solvents
- describe sterile injectable solutions and powders

### VII. KITS OF THE INVENTION

- describe kit components and container means

## EXAMPLES

- introduce examples of preferred embodiments of the invention

### Exemplary Materials and Methods

- isolate Stat3 SH2 domain structure
- prepare chemical databases for virtual ligand screening
- define binding pocket and perform flexible docking calculation
- select compounds for purchase and biochemical testing
- perform Stat3 SH2/pY-peptide binding assay
- perform immunoblot assay
- perform similarity screen
- perform electrophoretic mobility shift assay (EMSA)
- perform molecular modeling
- perform confocal and high-throughput fluorescence microscopy
- perform breast cancer cell line apoptosis assay

### Identification by VLS of Compounds that Blocked Stat3 Binding to its Phosphopeptide Ligand and Inhibited IL-6-Mediated Phosphorylation of STAT3

- identify compounds that blocked Stat3 binding and inhibited IL-6-mediated phosphorylation of Stat3

### Compound-Mediated Inhibition of Ligand-Stimulated Phosphorylation of STAT3 is Specific for Stat3 Vs. Stat1

- assess selectivity of compounds for Stat3 vs. Stat1

### Sequence Analysis and Molecular Modeling of the Interaction of Each Compound with the Stat3 Vs. Stat1 SH2 Domain

- compare amino acid sequence and structures of Stat1 and Stat3 SH2 domain
- analyze molecular modeling of compounds in complex with Stat3 SH2 domain

### Example 5

- describe Stat3 phosphorylation and nuclear accumulation
- introduce nuclear translocation assay
- present results of nuclear translocation assay
- describe destabilization of Stat3-DNA complexes
- present results of destabilization of Stat3-DNA complexes
- introduce apoptosis induction assay
- present results of apoptosis induction assay
- discuss significance of selective Stat3 compounds
- describe virtual ligand screening of compound libraries
- discuss previous Stat3 inhibitors
- describe development of small molecular inhibitors of Stat3
- discuss targeting cancer stem cells with Stat5 inhibitors
- introduce stem cell hypothesis
- discuss role of Stat3 in stem cells
- describe potential applications of Stat3 chemical probes
- introduce Stat3 and its role in embryonic stem cell maintenance and leukemia
- describe acute leukemia and its subtypes
- explain the role of Stat3 in leukemic stem cell survival
- introduce retroviral transduction and transformation assays (RTTAs) for studying fusion proteins
- describe the use of RTTA for drug discovery and identifying Stat3 chemical probes
- introduce the exemplary approach for Stat5 inhibitors for cancer stem cells
- describe the development of small molecule Stat3 probes and their features
- explain the identification of 1st generation Stat3 chemical probes
- describe the identification of 2nd generation Stat3 chemical probes
- explain the structure-activity relationship (SAR) analysis of 2nd generation Stat3 probes
- introduce medicinal chemistry for synthesizing 3rd generation 188-like sulfamide Stat5 probes
- describe the crystal structure of Stat3 and its binding area
- explain the medicinal chemistry approach for optimizing the activity and selectivity of sulfamide probes
- describe the modification of the sulfonyl group
- explain the modification of the 3-substituent of the naphthylamine ring
- describe the modifications of the 4, 5, and 6-positions of the naphthylamine ring
- identify Stat3-selective chemical probes
- describe SPR binding inhibition assay
- describe HTFM cytoplasm-to-nucleus translocation inhibition assays
- describe ligand-mediated pStat3 and pStat1 inhibition assays
- describe molecular modeling of probe-Stat3 interactions
- identify probes with one log or greater activity than 2nd generation probes
- examine effects on normal hematopoietic stem cells and leukemic stem cells
- describe screening of probes for activity against normal hematopoietic stem/progenitor cells
- describe testing of Stat3 probes for activity against leukemic stem cells
- describe RTTA assay
- describe testing of Stat3 probes for activity against leukemic stem cells in RTTA
- overview of breast cancer embodiments of the invention
- describe breast cancer stem cells
- describe targeting cancer stem cells
- describe breast cancer and Stat3
- describe role of Stat3 in breast cancer stem cells
- describe inhibition of Stat3 with small molecules
- describe targeting breast cancer stem cells with Stat3 inhibitors
- summarize breast cancer treatment strategy
- develop third generation Stat3 probes
- motivate medicinal chemistry
- describe SAR analysis
- summarize SPR assay
- describe HTFM examining inhibition
- motivate suppression of Stat3 pathway
- describe preclinical mammosphere forming efficiently models
- describe human xenograft models
- summarize enrichment of cancer stem cells
- describe preclinical models
- summarize gene transcription patterns
- describe development of first generation Stat3 probes
- motivate suppression of Stat5 pathway

## PUBLICATIONS

- list prior art
- list publications
- describe breast cancer cells
- discuss Stat3 signaling
- motivate Stat3 inhibitors
- summarize Stat3 structure
- describe Stat3 activation
- discuss Stat3 in cancer therapy
- summarize Stat3 isoforms
- describe Stat3 inhibitors in cancer treatment
- discuss Stat3 in breast cancer
- list publications
- reference STAT3 in breast carcinoma
- reference STAT3 in colon carcinoma
- reference STAT3 in prostate tumors
- reference STAT3 in cell lines
- reference STAT3 inhibitors
- reference STAT3 and chemotherapy
- reference STAT3 and apoptosis
- reference STAT3 and gene regulation
- reference STAT3 and cancer therapy

